TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.

ABSTRACT: The combination of tafasitamab and lenalidomide (tafa-lena) has demonstrated efficacy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), as evidenced by the L-MIND study. To investigate the therapeutic potential and safety profile of tafa-lena in real-life, we conducted a national multicentric retrospective study. Eighty-three patients with median age of 74 years were enrolled. The 49.4% of patients had a disease refractory to the first line therapy while 63.9% were refractory to the most recent one. The best overall response rate was 47% (28.9% complete remission). With a median follow-up of 16 months, the median overall survival (OS) was 8.6 months and the median progression-free survival (PFS) was 4.5 months. Disease-free survival and median duration of response were reac

SUBMITTER: Argnani L 

PROVIDER: S-EPMC12801173 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature